Where Will Tesla Stock Be in 3 Years? The electric-car maker's business is stabilizing, but the stock's three-year path comes down to one expensive bet.
A Director Trimmed SEI After a Big Run — is there room to run? Specializing in automation for the oil and gas sector, this Texas-based firm reported a notable insider sale amid strong stock performance.
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial Altimmune (
NASDAQ:ALT ) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, while also awaiting data from related alcohol-associated liver disease programs.
Microsoft Held Up as AI Chips Sold Off. Is It the Safer Megacap Bet Now? While much of the chip sector dropped sharply, the software and cloud giant barely budged -- and its diversified path to AI revenue may be the reason.
The $200 Billion Reason Amazon Could Be an Overlooked AI Winner The e-commerce and cloud giant's record spending is funding a fast-growing chip business that investors arguably aren't giving enough credit.
Trump Put His Name On A Washington Landmark—Now Staff Are Being Told To Take It Down Kennedy Center staff ordered to remove Trump's name per federal court ruling. Trump's broader effort to rename DC landmarks faces opposition.
Materion Director Trims His Stake — The Backlog Says the Story Isn't Over This advanced materials supplier to high-growth sectors just reported a notable insider sale, according to recent SEC filings.
Porch Group Mixes SaaS and Insurance — a tough combo to win with This home services and insurance software firm reported a notable insider sale as part of its ongoing executive selling cadence.
A Complete Guide to Buying Budget Flats in Siddharth Vihar IntroductionFinding a home that combines affordability, comfort, and connectivity is a priority for many homebuyers in the Delhi NCR region. Over the last
2 Tech Stocks I Would Buy Before SpaceX These are both highly profitable and have several revenue streams.
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a year of sharp share price declines.
Who Will Be The Next California Governor? Here's What Prediction Market Is Saying Xavier Becerra (D), former HHS Secretary, leads in Calif. governor race projections by Decision Desk HQ.
Merlin Stock Is Trending Overnight — Here's Why It Spiked Over 30% In After-Hours Session Merlin shares jumped 39.28% in after-hours trading after completing the Critical Design Review for its USSOCOM-backed C-130J autonomy program.
Align Technology CFO: Global Growth, DSOs Offset North America Demand Pressure Align Technology (
NASDAQ:ALGN ) CFO John Morici said the company continues to navigate a challenging but stable demand environment, with international markets and dental service organizations offsetting pressure in parts of North America.
Speaking at the Jefferies Global Healthcare Conference in a f
Which Growth Stock Is a Better Buy: Nvidia or Broadcom? Both of these chip giants are central to the AI build-out, but one looks like the better buy today.
A Slide Insurance Director Sells, but Florida's Insurance Market Is What to Watch This technology-driven insurer, focused on residential markets, reported significant insider selling in its latest SEC filing.
Top Economist Warns US Economy Is More Fragile Than It Looks: 'The Situation Is Tenuous' Moody's Mark Zandi warned the U.S. economy is growing below potential, raising risks of higher unemployment and slower growth.
Ford Stock Is Off to the Races. Can Its 55% Rally Continue? Ford took a $19.5 billion noncash charge just months ago and has turned that into a big triumph with its new venture.
Trump Floats Possible Meeting With Iran's Supreme Leader: Dow Futures Fall 62 Points While Oil Hovers Near $93 Stock futures fell and oil stayed near $93 as Trump floated talks with Iran's supreme leader amid ongoing geopolitical tensions.
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment Aldeyra Therapeutics (
NASDAQ:ALDX ) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions.
Speaking at a Jefferies fireside c
Massive News for Alphabet Stock Investors! Alphabet is signaling continues investments in AI.
Is Costco Stock an Undervalued Stock to Buy? Sales are booming as consumers flock to places that offer value.
